PATENT CLAIM ANALYSIS

Application Number: 15965741
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "300000"]

Abstract:
The present invention relates to SNS-595 and methods of treating cancer using the same.

Claim (Index 26):
A method for treating cancer comprising administering to a human patient having cancer (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in a dose of about 10 mg/m 2 -100 mg/m 2  and a therapeutically effective amount of a second agent selected from an agent that inhibits nonhomologous end joining repair, an apoptosis enhancing agent, an alkylating agent, an anti-neoplastic antibiotic, a platinum coordination complex and a topoisomerase II inhibitor.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13794583', '14462439', '11991349', '11080102', '11080283']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.682891797748906
- 35 USC 102 Novelty (BERT): 0.4439543513767454
- Combined Prediction Score: 0.6589980531116899
- Mean Citation Score: 124.899014
- Max Citation Score: 135.16843
- Similarity Product: 120.91855605478882

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test